South Carolina's highest court cut a $327 million verdict against Johnson & Johnson by more than half while refusing to throw out a jury's finding that it deceptively marketed the antipsychotic drug Risperdal as safer than competing medicines. In a 4-1 ruling Wednesday, the Supreme Court cited a three- year limit on claims alleging Johnson & Johnson's Janssen unit violated South Carolina's Unfair Trade Practices Act.